Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis

Authors:

Michela Luciano, Helene Sieberer, Peter W. Krenn, Hieu-Hoa Dang, Julia Vetter, Theresa Neuper, Diana Amend, Constantin Blöchl, Christian X. Weichenberger, Anna Eglseer, Michael S. Unger, Ancuela Andosch, Philip Steiner, Daniel Neureiter, Renate Bauer, Laura Hummer, Suzana Tesanovic, Stephanie Binder, Dominik P. Elmer, Helen Strandt, Susanne Schaller, Dirk Strunk, Lisa Pleyer, Richard Greil, Stephan Winkler, Tanja N. Hartmann, Dirk Schmidt-Arras, Christian G. Huber, Fritz Aberger, Jutta Horejs-Hoeck

Keywords:

Acute myeloid leukemia; Apoptosis; eIF2α; NLRP3; PERK

Abstract:

Background: Acute myeloid leukemia (AML) is characterized by the abnormal proliferation of myeloid precursor cells and presents significant challenges in treatment due to its heterogeneity. Recently, the NLRP3 inflammasome has emerged as a potential contributor to AML pathogenesis, although its precise mechanisms remain poorly understood.

Methods: Public genome datasets were utilized to evaluate the expression of NLRP3 inflammasome-related genes (IL-1β, IL-18, ASC, and NLRP3) in AML patients compared to healthy individuals. CRISPR/Cas9 technology was employed to generate NLRP3-deficient MOLM-13 AML cells, followed by comprehensive characterization using real-time PCR, western blotting, FACS analysis, and transmission electron and immunofluorescence microscopy. Proteomic analyses were conducted to identify NLRP3-dependent alterations in protein levels, with a focus on the eIF2 kinase PERK-mediated signaling pathways. Additionally, in vivo studies were performed using a leukemic mouse model to elucidate the pathogenic role of NLRP3 in AML.

Results: Elevated expression of NLRP3 was significantly associated with diminished overall survival in AML patients. Genetic deletion, pharmacological inhibition and silencing by RNA interference of NLRP3 led to decreased AML cell survival through the induction of apoptosis. Proteomic analyses uncovered NLRP3-dependent alterations in protein translation, characterized by enhanced eIF2α phosphorylation in NLRP3-deficient AML cells. Moreover, inhibition of PERK-mediated eIF2α phosphorylation reduced apoptosis by downregulating pro-apoptotic Bcl-2 family members. In vivo studies demonstrated reduced leukemic burden in mice engrafted with NLRP3 knockout AML cells, as evidenced by alleviated leukemic symptoms.

Conclusion: Our findings elucidate the involvement of the NLRP3/PERK/eIF2 axis as a novel driver of AML cell survival. Targeting NLRP3-induced signaling pathways, particularly through the PERK/eIF2 axis, presents a promising therapeutic strategy for AML intervention. These insights into the role of the NLRP3 inflammasome offer potential avenues for improving the prognosis and treatment outcomes of AML patients.

< Back to publications

Full article >